SCHEMBL5017654

SCHEMBL5017654

Clc1cc(-c2nccs2)nc(-c2cccs2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.44
RAB9A P51151 3/20 0.42
MAPT P10636 3/20 0.41
NPC1 O15118 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CYP1A1 P04798 4/20 0.41
CYP1A2 P05177 4/20 0.41
CYP1B1 Q16678 4/20 0.41
HSP90AA1 P07900 1/20 0.41
ADORA2A P29274 3/20 0.40
ADORA3 P0DMS8 2/20 0.40
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 2/20 0.40
MEN1 O00255 2/20 0.40
HPGD P15428 2/20 0.40
KMT2A Q03164 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5017693 0.85 HSP90AA1 (0.47) CYP19A1RAB9AMAPTNPC1SMN1; SMN2
SCHEMBL5026281 0.85 CYP19A1 (0.48) CYP19A1RAB9AMAPTNPC1SMN1; SMN2
SCHEMBL9438481 0.82 ADORA2A (0.54) CYP19A1RAB9AMAPTNPC1SMN1; SMN2
SCHEMBL5026243 0.80 KDM4E (0.48) CYP19A1RAB9AMAPTNPC1CYP1A2
SCHEMBL5016068 0.77 ADORA2A (0.50) CYP19A1RAB9AMAPTNPC1SMN1; SMN2
SCHEMBL4648 0.76 PDPK1 (0.56) CYP19A1RAB9AMAPTNPC1HSP90AA1
SCHEMBL1489623 0.75 ADORA2A (0.61) ADORA2AADORA3ADORA1
SCHEMBL9310588 0.75 NPC1 (0.45) RAB9AMAPTNPC1SMN1; SMN2ADORA2A
SCHEMBL13090458 0.75 ADORA2A (0.47) RAB9AMAPTNPC1CYP1A1CYP1A2
SCHEMBL929587 0.74 HSP90AA1 (0.57) RAB9ACYP1A1CYP1A2CYP1B1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
CN-1953975-A 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists ALMIRALL PRODESFARMA AG (CH) 2007-04-25 CN disclosed
EP-1697351-A1 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma AG (CH) 2006-09-06 EP disclosed
WO-2005058883-A1 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists ADORA2A, ADORA3, ADORA1 CYP19A1 3285/4885RAB9A 942/4885MAPT 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.